00690.HK
Uni-Bio Science Group Limited
HKSE · Healthcare · Biotechnology · HK
HKD 0.06
+3.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 586.2M | 553.0M | 484.7M | 440.3M |
| Cost of Revenue | 200.1M | 98.7M | 91.9M | 91.9M | 105.4M |
| Gross Profit | 939.3M | 487.6M | 461.1M | 392.8M | 334.9M |
| Operating Expenses | |||||
| R&D Expense | 94.0M | 44.1M | 56.7M | 36.4M | 35.8M |
| SG&A Expense | 693.6M | 353.5M | 312.4M | 288.7M | 258.3M |
| General & Admin Expense | 87.4M | 60.4M | 50.7M | 47.4M | 47.0M |
| Selling & Marketing Expense | 436.5M | 292.0M | 261.6M | 241.3M | 211.3M |
| Other Expenses | 190.2M | — | 2.1M | — | (1.5M) |
| Total Operating Expenses | 977.7M | 397.6M | 371.2M | 325.1M | 292.6M |
| Cost and Expenses | 1.2B | 496.3M | 463.1M | 416.9M | 400.9M |
| Operating Income (EBIT) | (38.5M) | 90.0M | 89.9M | 67.8M | 38.1M |
| Non-Operating | |||||
| Interest Income | — | 3.1M | 3.4M | 1.4M | 1.3M |
| Interest Expense | 3.3M | 1.5M | 1.2M | 783.0K | 376.0K |
| Net Interest Income | (3.3M) | 1.6M | 2.2M | 567.0K | 921.0K |
| Other Non-Op Income/Expense | 196.9M | 11.6M | 1.3M | 8.1M | 5.2M |
| Non-Operating Income (excl Interest) | (199.1M) | (7.3M) | (2.5M) | (8.9M) | (4.3M) |
| EBT (Pre-Tax Income) | 158.5M | 101.5M | 91.2M | 75.9M | 43.3M |
| Income Tax Expense | 18.6M | 8.2M | 8.4M | 5.0M | 4.8M |
| Bottom Line | |||||
| Net Income | 139.9M | 93.3M | 82.8M | 70.9M | 38.5M |
| Earnings from Cont. Ops | 139.9M | 93.3M | 82.8M | 70.9M | 38.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 139.9M | 93.3M | 82.8M | 70.9M | 38.5M |
| Per Share | |||||
| Basic EPS | HK$0.02 | HK$0.02 | HK$0.01 | HK$0.01 | HK$0.01 |
| Diluted EPS | HK$0.02 | HK$0.02 | HK$0.01 | HK$0.01 | HK$0.01 |
| Revenue Per Share | HK$0.19 | HK$0.10 | HK$0.09 | HK$0.08 | HK$0.07 |
| Shares | |||||
| Basic Shares Outstanding | 6.0B | 6.0B | 6.1B | 6.4B | 6.4B |
| Diluted Shares Outstanding | 6.0B | 6.0B | 6.1B | 6.4B | 6.4B |
| Profitability Metrics | |||||
| EBITDA | 190.3M | 108.3M | 113.6M | 93.6M | 61.2M |
| D&A | 29.6M | 11.1M | 21.4M | 16.9M | 17.5M |
| EBIT | 160.7M | 97.2M | 92.4M | 76.7M | 43.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026